Biotech stocks to buy now in pursuit of market-beating returns feature several promising companies that are seeking to develop important new pharmaceutical treatments or cures for life-threatening or debilitating medical conditions.

People who like to back companies that will help to improve health and happiness may feel doubly rewarded if they also can receive a superior return on their investments in biotech stocks to buy now. Such stocks come with uncertainty and risk, but the rewards for the biggest successes can help to more than compensate for the ones that fail to fulfill their hoped-for promise.

“The real thrill of biotech investing is the journey from pioneering scientific insight to product that actually changes lives,” said Hilary Kramer, who hosts a national radio investment program called “ Millionaire Maker” and leads the 2-Day Trader service that has netted profits in 20 of its first 25 trades for an average return of 8.70 percent.

Until these biotechnology companies gain final Food and Drug Administration (FDA) approval for their potential breakthrough new treatments, they often are on a risk-filled journey that requires continued funding of costly medical research with the goal of successfully producing an effective and marketable new pharmaceutical. The process will take years and potentially billions of dollars in development costs, with no guarantee of success in a painstaking search of the next great cure.

Paul Dykewicz interviews Hilary Kramer, whose new 2-Day Trader service is 20 out of 25 in recommending profitable trades averaging 8.7 percent returns since its launch.

To read the rest of Paul’s weekly investment column, please click here.

Paul Dykewicz, www.pauldykewicz.com, is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street Journal, Investor’s Business Daily, USA Today, the Journal of Commerce,Seeking Alpha, GuruFocus and other publications and websites. Paul is the editor of StockInvestor.com and DividendInvestor.com, a writer for both websites and a columnist. He further is the editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul previously served as business editor of Baltimore’s Daily Record newspaper. Paul also is the author of an inspirational book, “Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain,” with a foreword by former national championship-winning football coach Lou Holtz. Follow Paul on Twitter @PaulDykewicz.